LUCIUS 卢修斯 艾拉司群 Elacestrant乳腺癌

艾拉司群

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Elacestrant

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:
tach tilm-coated tabict contains Elacestrant

乳腺癌

dinydrochlonde 400mg equrvalent to

Elacestran

LUCIUS

HARMACEUTICALS

Lucitlace is an estrogen receptor antagonist
indicated for.

treatment of postmenopausal women or adult
men, with ERpositive, HER2-negative, ESRI-
hrarcu sovanceo of metastanc oreast caneer

LuciElace

dasiou tonowing at least on
mne of eodocrine therapy.
. Select patients for treatment with LuciElace
based on the presence of ESRI mutations.

Elacestrant Tablets

FDA批准

. The recommended dosage of LuciElace is one
345 mg. oncedaily, with food.
*Dose interruption, reduction, or permanent

345mg

discontinuation may be required due to adversc
reactions.
rage: in a dry place and store at 20°℃ 1o 25°C
Warning:
Keep medicine out of reach of Children. Do nol

Rx Only

ucitlace during Pregnancy and
Lactation

PLEASE SEE PACKAGEINSERT
Manufactured and Marketed by:

权威认证

LUCIUS

Thongmang village, Xaythany district
Vientiane Capital, Laos
Warning : To De sold by retail on preseri

ol Tegisicred physicians only ond oo tleee
Dy the phoaerny
ag physiciar

only, and as directe

30 Tablets

口碑质量

适应症:
艾拉司群是一种雌激素受体拮抗剂,适用于治疗绝经
后女性或成年男性,ER阳性、HER2阴性、ESR1突变
的晚期或转移性乳腺癌,且在接受至少一线内分泌治

疗后病情出现进展。
推荐剂量:
1、根据ESR1突变情况选择接受艾拉司群治疗的患者。

2、推荐剂量为每日口服一次,每次345mg:随餐服用。
3、可因不良反应而中断、减少或永久停药。